会阴重建手术无阿片类药物路径评估:一项为期1年的试点研究
本研究前瞻性随访2022年7月至2023年6月由单一术者完成的67例会阴重建手术患者,实施标准化非阿片围手术期疼痛管理路径。术后6/67(9%)患者获阿片类药物处方,无重复处方;26例在恢复室接受阿片类药物的患者中2例(7.6%)出院时获处方。作者认为无阿片路径适用于未使用过阿片类药物的男性会阴重建手术患者。
要点
- 67例会阴重建手术中6例(9%)术后获阿片处方,无重复处方。
- 恢复室使用阿片类药物的26例中仅2例(7.6%)出院时获处方。
- 15例(22%)在30天内因疼痛沟通,多与膀胱痉挛管理相关。
核心结论
- 无阿片类药物路径适用于未使用过阿片类药物的男性会阴重建手术患者。
- 必要时,出院后针对突破性疼痛应采用电子阿片类药物处方。
研究设计与样本
- 前瞻性随访2022年7月至2023年6月由单一术者完成的会阴重建手术(尿道成形术、人工尿道括约肌、尿道吊带)患者。
- 围手术期实施标准化非阿片路径,术中局部麻醉包括脂质体布比卡因混合0.25%布比卡因。
- 阿片类药物由麻醉人员在恢复室酌情给予;自2022年7月起,常规做法为除非恢复区疼痛控制不佳,否则不开具术后阿片类药物处方。
- 通过电子健康记录追踪术后沟通事件和阿片类药物处方以评估无阿片路径效果。
主要发现
- 67例患者符合标准,其中64/67在门诊环境下完成手术。
- 6/67(9%)患者术后获阿片类药物处方,4例与术后疼痛相关,2例与慢性疼痛相关;无重复处方。
- 恢复室接受阿片类药物的26例患者中,2例(7.6%)出院时获阿片类药物处方。
- 15/67(22%)患者在30天内因疼痛相关沟通事件,最常见与膀胱痉挛管理相关;仅2次沟通事件导致电子阿片类药物处方。
临床怎么用
- 本研究中心的做法是自2022年7月起,除非恢复区疼痛控制不佳,否则不开具术后阿片类药物处方。
- 作者认为无阿片类药物路径适用于未使用过阿片类药物的男性会阴重建手术患者。
- 作者认为必要时出院后针对突破性疼痛应采用电子阿片类药物处方。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the impact of a standardized perioperative pain management pathway on postoperative opioid prescribing practices following male perineal reconstructive surgery at our institution. METHODS: Patients undergoing perineal reconstructive surgery (urethroplasty, artificial urinary sphincter, urethral sling) by a single surgeon from July 2022 to June 2023 were prospectively followed. A standardized nonopioid pathway was implemented in the perioperative period. Intraoperative local anesthetic included liposomal bupivacaine mixed with 0.25% bupivacaine. Opioids are administered in the recovery room at the discretion of anesthesiology providers. As of July 2022, our standard practice does not include a postoperative opioid prescription unless pain is poorly controlled in the recovery area. Postoperative communication encounters and opioid prescriptions were tracked through the electronic health record (EHR) in order to assess the efficacy of an opioid-free pathway. RESULTS: Sixty-seven patients met the criteria during the study period, 64/67 performed in an outpatient setting. 6/67 (9%) patients were prescribed an opioid postoperatively; 4 related to post-surgical pain, and 2 related to chronic pain. No refills were prescribed. Of the 26 patients who received an opioid in the recovery area, 2 (7.6%) were prescribed an opioid at discharge. 15/67 (22%) patients had a communication encounter related to pain within 30 days, most commonly related to bladder spasm management. Only 2 of these encounters resulted in an electronic opioid prescription. CONCLUSION: An opioid-free pathway is appropriate for opioid naive men undergoing perineal reconstructive surgery. When necessary, electronic opioid prescribing should be employed following discharge for breakthrough pain.
引用
- Pence ST, Findlay BL, Bearrick EN, et al. Evaluation of an Opioid-free Pathway for Perineal Reconstructive Surgery: A 1-year Pilot Study. Urology. 2024. PMID: 38677369. doi:10.1016/j.urology.2024.04.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。